China: A new study, published in Diabetes, Metabolic Syndrome and Obesity, has shed light on the potential role of specific ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...